Oral Cannabidiol for Opioid Withdrawal

Status Completed

Clinical Trial Summary

This pilot study will examine the safety of the cannabinoid cannabidiol (Epidiolex) in a human laboratory model of clinically relevant withdrawal. The study will be a residential within-subject comparison; all participants will receive placebo dosing and active cannabidiol. Results may be used to support an R01 grant application to more closely examine this hypothesis.

Clinical Trial Description

Based on preclinical research and emerging human research, cannabidiol (CBD; a major constituent of the cannabis plant) is a promising pharmacotherapy for the treatment of opioid withdrawal. Most recently, CBD decreased cue-induced craving and anxiety (two common withdrawal symptoms) among abstinent heroin-dependent individuals relative to placebo. As of June 2018, Epidiolex, an oral formulation of plant-derived pure CBD, has been approved by the U.S. Food and Drug Administration (FDA) for treating severe forms of epilepsy and can be prescribed for other off-label indications. Epidiolex has a low side effect and high safety profile. Given the recent FDA approval of Epidiolex, and a growing interest to develop existing pharmaceuticals to address issues related to Opioid Use Disorder (OUD) and its recovery, the investigators are proposing a pilot study to examine the safety of Epidiolex in a human laboratory model of clinically relevant withdrawal. The study will be a residential within-subject comparison; methadone-maintained participants will undergo spontaneous withdrawal and receive placebo dosing and active cannabidiol. Data collected for this study will establish: (1) the safety of administering two dosing regimens of Epidiolex within the investigators' withdrawal paradigm and (2) the feasibility of the investigators' withdrawal paradigm for demonstrating clinically meaningful increases in withdrawal. Results may be used to support an R01 grant application to more closely examine this hypothesis. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04238754
Study type	Interventional
Source	Johns Hopkins University
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	November 1, 2020
Completion date	June 30, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06021431` - Virtual Reality Cognitive-Affective Training for Opioid Use Disorder- A Phase 2 RCT	N/A
Completed	`NCT06266572` - Overcoming Stigma and Improving Outcomes for SUDs Through Education, Engagement, and Empowerment	Phase 1
Recruiting	`NCT05037682` - Pain and Opioid Management in Older Adults	N/A
Completed	`NCT06200740` - Remotely Observed Methadone Evaluation	N/A
Not yet recruiting	`NCT06441604` - Extended-release Buprenorphine as a Novel Low-dose Induction Strategy	Phase 2
Recruiting	`NCT06028126` - Superficial Parasternal Intercostal Plane Block in Cardiac Surgery Trial	N/A
Completed	`NCT02559973` - Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder	Phase 1
Completed	`NCT02593474` - Medication-Assisted Treatment for Youth With Substance Use Disorders	Phase 1
Completed	`NCT02440256` - Expanded HIV Care in Opioid Substitution Treatment (EHOST) Trial	N/A
Completed	`NCT05587998` - A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.	Phase 1
Terminated	`NCT04577144` - An Observational Study of Environmental and Socioeconomic Factors in Opioid Recovery - Long Term
Recruiting	`NCT06001437` - Following Outcomes Remotely Within Addiction Recovery Domains
Recruiting	`NCT05976646` - Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion	Phase 1/Phase 2
Completed	`NCT05546229` - Assessment of Methadone and Buprenorphine in Interstitial Fluid
Not yet recruiting	`NCT06104280` - Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment	N/A
Not yet recruiting	`NCT06416020` - Integrating MOUD in African American Community Settings (Better Together)	N/A
Recruiting	`NCT06206291` - Cannabidiol for Opioid Addiction	Phase 2
Completed	`NCT05552040` - START NOW in the Treatment of Opioid Addicted Individuals	N/A
Recruiting	`NCT05459922` - Adjunctive Bright Light Therapy for Opioid Use Disorder	N/A
Recruiting	`NCT05343169` - Community-based Education, Navigation, and Support Intervention for Military Veterans	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.